EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis

Nicole Macagno iD, Luca Mastorino iD, Michela Ortoncelli, Silvia Borriello, Chiara Astrua, Anna Verrone, Elena Stroppiana, Paolo Dapavo, Niccolò Siliquini, Simone Ribero iD, Pietro Quaglino

Journal of Clinical Medicine · 31.10.2024 · 13 (21) · 6546

DOI: 10.3390/jcm13216546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 31.10.2024. Verfasst von Nicole Macagno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Patients with treated solid tumors (TST) are a highly heterogeneous and difficult-to-treat population due to the risk of disease progression/recurrence or infection.

Methods

We conducted an observational, retrospective, single-center study at the Dermatology Clinic of Turin with a focus on the special population of cancer patients with psoriasis treated with biologics.

Results

As of July 2023, 52 psoriatic patients with a prior/concomitant history of malignancy had taken biologic drugs. The median age was 67 years, and the median age of cancer onset was 55 years. The most common tumors were gastrointestinal cancer and melanoma. After the tumor diagnosis, 61% received an anti-IL17 drug; 37 patients continued the initiated biologic therapy, while 12 switched drugs due to secondary inefficacy. The estimated biologic DS was 55.6% at 50 months. Evidence suggests that IL-17 is a key pathogenic factor involved in tumorigenesis, resulting in a lower risk of malignancies in subjects managed with IL-17 inhibitors. Similarly, IL-23 plays a role in suppressing innate immunity and promoting tumor and metastases development. This is a consistent real-life case series that support the use of biologic drugs in patients with TST.

Conclusions

IL-23 and IL-17 inhibitors, being immunomodulators rather than immunosuppressants, may be a safe option for patients in an active oncological setting and for immune-correlated adverse events.

Schlagwörter

Stichwörter der Autor:innen

PASIbiologicscanceroncologypsoriasissafetytumor

Autor:innen und Institutionen

  • Dermatology Clinic, Medical Sciences Department, University of Turin, 10123 Torino, Italy.

ORCID-Profile: Nicole Macagno, Luca Mastorino, Simone Ribero

Zitieren

APA

Macagno, N., Mastorino, L., Ortoncelli, M., Borriello, S., Astrua, C., Verrone, A., Stroppiana, E., Dapavo, P., Siliquini, N., Ribero, S., & Quaglino, P. (2024). Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis. Journal of Clinical Medicine, 13(21), 6546. https://doi.org/10.3390/jcm13216546

Vancouver

Macagno N, Mastorino L, Ortoncelli M, Borriello S, Astrua C, Verrone A, et al. Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis. Journal of Clinical Medicine. 2024;13(21):6546. doi:10.3390/jcm13216546

BibTeX
@article{Macagno2024,
  author = {Macagno, Nicole and Mastorino, Luca and Ortoncelli, Michela and Borriello, Silvia and Astrua, Chiara and Verrone, Anna and Stroppiana, Elena and Dapavo, Paolo and Siliquini, Niccolò and Ribero, Simone and Quaglino, Pietro},
  title = {Drug Survival and Clinical Course of Patients with Cancer Treated with Biologic Therapy for Psoriasis},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  pages = {6546},
  doi = {10.3390/jcm13216546}
}
Kostenlos starten →